The White House said Friday it’s adding three drugs for diabetes and lung disease to the self-pay platform TrumpRx, as the ...

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) ...

From online forums to the clinic, people have reported that diabetes and weight-loss drugs such as Ozempic and Wegovy can dramatically quell their compulsive behaviors—including cravings for alcohol ...

People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness ...

New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.

Researchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified for GLP-1 treatment had a higher risk of type 2 diabetes, suggesting that ...

A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, ...

A new study suggests that almost half of people stopping GLP-1 weight-loss drugs may keep the weight off. However, many of these people continued other forms of treatment after stopping GLP-1 drugs.